Cargando…
MiR‐145 in cancer therapy resistance and sensitivity: A comprehensive review
MircoRNA (miRNA) are a group of small, non–coding, regulatory RNA with an average length of approximately 22 nucleotides, which mostly modulate gene expression post–transcriptionally through complementary binding to the 3ʹ‐untranslated region (3ʹ‐UTR) of multiple target genes. Emerging evidence has...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469794/ https://www.ncbi.nlm.nih.gov/pubmed/32506767 http://dx.doi.org/10.1111/cas.14517 |
_version_ | 1783578466892906496 |
---|---|
author | Xu, Wenxiu Hua, Yuting Deng, Fei Wang, Dandan Wu, Yang Zhang, Wei Tang, Jinhai |
author_facet | Xu, Wenxiu Hua, Yuting Deng, Fei Wang, Dandan Wu, Yang Zhang, Wei Tang, Jinhai |
author_sort | Xu, Wenxiu |
collection | PubMed |
description | MircoRNA (miRNA) are a group of small, non–coding, regulatory RNA with an average length of approximately 22 nucleotides, which mostly modulate gene expression post–transcriptionally through complementary binding to the 3ʹ‐untranslated region (3ʹ‐UTR) of multiple target genes. Emerging evidence has shown that miRNA are frequently dysregulated in a variety of human malignancies. Among them, microRNA‐145 (miR‐145) has been increasingly identified as a critical suppressor of carcinogenesis and therapeutic resistance. Resistance to tumor therapy is a challenge in cancer treatment due to the daunting range of resistance mechanisms. We reviewed the status quo of recent advancements in the knowledge of the functional role of miR‐145 in therapeutic resistance and the tumor microenvironment. It may serve as an innovative biomarker for therapeutic response and cancer prognosis. |
format | Online Article Text |
id | pubmed-7469794 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-74697942020-09-09 MiR‐145 in cancer therapy resistance and sensitivity: A comprehensive review Xu, Wenxiu Hua, Yuting Deng, Fei Wang, Dandan Wu, Yang Zhang, Wei Tang, Jinhai Cancer Sci Review Articles MircoRNA (miRNA) are a group of small, non–coding, regulatory RNA with an average length of approximately 22 nucleotides, which mostly modulate gene expression post–transcriptionally through complementary binding to the 3ʹ‐untranslated region (3ʹ‐UTR) of multiple target genes. Emerging evidence has shown that miRNA are frequently dysregulated in a variety of human malignancies. Among them, microRNA‐145 (miR‐145) has been increasingly identified as a critical suppressor of carcinogenesis and therapeutic resistance. Resistance to tumor therapy is a challenge in cancer treatment due to the daunting range of resistance mechanisms. We reviewed the status quo of recent advancements in the knowledge of the functional role of miR‐145 in therapeutic resistance and the tumor microenvironment. It may serve as an innovative biomarker for therapeutic response and cancer prognosis. John Wiley and Sons Inc. 2020-07-08 2020-09 /pmc/articles/PMC7469794/ /pubmed/32506767 http://dx.doi.org/10.1111/cas.14517 Text en © 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Review Articles Xu, Wenxiu Hua, Yuting Deng, Fei Wang, Dandan Wu, Yang Zhang, Wei Tang, Jinhai MiR‐145 in cancer therapy resistance and sensitivity: A comprehensive review |
title | MiR‐145 in cancer therapy resistance and sensitivity: A comprehensive review |
title_full | MiR‐145 in cancer therapy resistance and sensitivity: A comprehensive review |
title_fullStr | MiR‐145 in cancer therapy resistance and sensitivity: A comprehensive review |
title_full_unstemmed | MiR‐145 in cancer therapy resistance and sensitivity: A comprehensive review |
title_short | MiR‐145 in cancer therapy resistance and sensitivity: A comprehensive review |
title_sort | mir‐145 in cancer therapy resistance and sensitivity: a comprehensive review |
topic | Review Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469794/ https://www.ncbi.nlm.nih.gov/pubmed/32506767 http://dx.doi.org/10.1111/cas.14517 |
work_keys_str_mv | AT xuwenxiu mir145incancertherapyresistanceandsensitivityacomprehensivereview AT huayuting mir145incancertherapyresistanceandsensitivityacomprehensivereview AT dengfei mir145incancertherapyresistanceandsensitivityacomprehensivereview AT wangdandan mir145incancertherapyresistanceandsensitivityacomprehensivereview AT wuyang mir145incancertherapyresistanceandsensitivityacomprehensivereview AT zhangwei mir145incancertherapyresistanceandsensitivityacomprehensivereview AT tangjinhai mir145incancertherapyresistanceandsensitivityacomprehensivereview |